The connection between metabolic disorders and neurodegeneration is a significant area of research. Evidence suggests a reciprocal relationship where insulin resistance, obesity, and chronic metabolic inflammation are linked to changes in brain function, including neuronal survival, synaptic plasticity, and neuroimmune processes. **GLP-1** receptor agonists, initially developed for diabetes and weight management, are being explored as potential treatments for neurodegenerative conditions like Alzheimer’s and Parkinson’s disease. These agonists may influence neuronal activity through **PKA** activation, reduce inflammation via **NLRP3** suppression, promote mitochondrial function, and restore **AQP4** localization for enhanced waste clearance. Support for these mechanisms comes primarily from preclinical models and indirect human data.
Key Clinical Findings
Currently, direct human evidence for these central nervous system mechanisms is limited. Two large clinical trials, **EVOKE/EVOKE+** in Alzheimer’s disease and **Exenatide-PD3** in Parkinson’s disease, did not show a statistically significant benefit on their primary clinical endpoints. These trials, despite prior biomarker and epidemiological findings, failed to confirm the anticipated therapeutic effects.
Synthesis and Future Directions
The review synthesizes current understanding of brain insulin signaling, central **GLP-1** biology, obesity-related neuroinflammation, and the translational evidence surrounding metabolic therapies for neurodegenerative diseases. It highlights the need for further investigation into **CNS** target engagement, optimal dosing strategies, and the potential for achieving disease-modifying efficacy with **GLP-1** receptor agonists.